[
  {
    "ts": "2025-11-10T06:04:51+00:00",
    "headline": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
    "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
    "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5bfa6687-1864-386e-92f9-c665cf7db08e",
      "content": {
        "id": "5bfa6687-1864-386e-92f9-c665cf7db08e",
        "contentType": "STORY",
        "title": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
        "description": "",
        "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
        "pubDate": "2025-11-10T06:04:51Z",
        "displayTime": "2025-11-10T06:04:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r4r1G1eFsl6QfUy6gLgJHg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nUAELTZkZtSvOC2PvSjdBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:34:31+00:00",
    "headline": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
    "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
    "url": "https://www.pharmaceutical-technology.com/news/sanegenebio-lilly-rnai-licensing-deal/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "13183824-c983-379b-a43a-0e431e9f2a02",
      "content": {
        "id": "13183824-c983-379b-a43a-0e431e9f2a02",
        "contentType": "STORY",
        "title": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
        "description": "",
        "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
        "pubDate": "2025-11-10T09:34:31Z",
        "displayTime": "2025-11-10T09:34:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5",
          "originalWidth": 1440,
          "originalHeight": 812,
          "caption": "SanegeneBio pipeline features experimental treatments for cardiometabolic conditions",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjZc0yDiT_LqG1mGmyb3mg--~B/aD04MTI7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5.cf.webp",
              "width": 1440,
              "height": 812,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_8U_5jt8oe1aTOiIv2TJBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/sanegenebio-lilly-rnai-licensing-deal/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sanegenebio-lilly-sign-rnai-licence-093431595.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T04:33:52+00:00",
    "headline": "2 Growth Stocks with All-Star Potential and 1 We Question",
    "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
    "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7165ce2f-8fe2-3a7a-a332-48252a30a9dd",
      "content": {
        "id": "7165ce2f-8fe2-3a7a-a332-48252a30a9dd",
        "contentType": "STORY",
        "title": "2 Growth Stocks with All-Star Potential and 1 We Question",
        "description": "",
        "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
        "pubDate": "2025-11-10T04:33:52Z",
        "displayTime": "2025-11-10T04:33:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe",
          "originalWidth": 2400,
          "originalHeight": 1603,
          "caption": "DDOG Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u.pYFSeNAk6XGh8hFOPaw--~B/aD0xNjAzO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe.cf.webp",
              "width": 2400,
              "height": 1603,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/avylLmnwtDoHvc_qca5ARQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "USPH"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DDOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:18:45+00:00",
    "headline": "Novo Rises After Bowing Out of Metsera Takeover Battle",
    "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
    "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
      "content": {
        "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
        "contentType": "STORY",
        "title": "Novo Rises After Bowing Out of Metsera Takeover Battle",
        "description": "",
        "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
        "pubDate": "2025-11-10T09:18:45Z",
        "displayTime": "2025-11-10T09:18:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fmXrJtbI3H5zCMXkv.hLZw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i3MlmOJYQDWFClE3QXhFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:13:44+00:00",
    "headline": "Did Walmart's (WMT) New Healthcare and Logistics Moves Just Shift Its Investment Narrative?",
    "summary": "Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...",
    "url": "https://finance.yahoo.com/news/did-walmarts-wmt-healthcare-logistics-111344844.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "1ade6a88-af24-36b9-9ac3-91d17d0ecbdc",
      "content": {
        "id": "1ade6a88-af24-36b9-9ac3-91d17d0ecbdc",
        "contentType": "STORY",
        "title": "Did Walmart's (WMT) New Healthcare and Logistics Moves Just Shift Its Investment Narrative?",
        "description": "",
        "summary": "Walmart recently expanded its health and wellness offerings by partnering with Eli Lilly to provide direct-to-consumer access for the weight-loss drug Zepbound in its pharmacies, while also integrating GOFO's nationwide logistics services to strengthen its e-commerce marketplace delivery capabilities. These collaborations underscore Walmart’s drive to enhance healthcare access and delivery efficiency, reflecting a multi-faceted approach to digital transformation and marketplace...",
        "pubDate": "2025-11-10T11:13:44Z",
        "displayTime": "2025-11-10T11:13:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r4r1G1eFsl6QfUy6gLgJHg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nUAELTZkZtSvOC2PvSjdBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-walmarts-wmt-healthcare-logistics-111344844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-walmarts-wmt-healthcare-logistics-111344844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:06:27+00:00",
    "headline": "Novo's $1,349 Shot Just Got Squeezed: Is Lilly Winning the Weight-Loss War?",
    "summary": "Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.",
    "url": "https://finance.yahoo.com/news/novos-1-349-shot-just-110627397.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "a3532613-b722-3f7a-8910-c512b710acfc",
      "content": {
        "id": "a3532613-b722-3f7a-8910-c512b710acfc",
        "contentType": "STORY",
        "title": "Novo's $1,349 Shot Just Got Squeezed: Is Lilly Winning the Weight-Loss War?",
        "description": "",
        "summary": "Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.",
        "pubDate": "2025-11-10T11:06:27Z",
        "displayTime": "2025-11-10T11:06:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-1-349-shot-just-110627397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-1-349-shot-just-110627397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:00:00+00:00",
    "headline": "MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology",
    "summary": "LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbo",
    "url": "https://finance.yahoo.com/news/meiragtx-enters-strategic-collaboration-eli-120000433.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "a559f10f-499d-38dc-abb2-e728520fd6bf",
      "content": {
        "id": "a559f10f-499d-38dc-abb2-e728520fd6bf",
        "contentType": "STORY",
        "title": "MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology",
        "description": "",
        "summary": "LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”). MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) owing to genetic deficiency of Aryl-hydrocarbo",
        "pubDate": "2025-11-10T12:00:00Z",
        "displayTime": "2025-11-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/7d3a2fa2ab3c203b44f402dd7f69c584",
          "originalWidth": 404,
          "originalHeight": 80,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LLrv0pWs64Owa1k4_MUk_Q--~B/aD04MDt3PTQwNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7d3a2fa2ab3c203b44f402dd7f69c584.cf.webp",
              "width": 404,
              "height": 80,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zCWlLjc7lkVTrKj0pb0egA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7d3a2fa2ab3c203b44f402dd7f69c584.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/meiragtx-enters-strategic-collaboration-eli-120000433.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/meiragtx-enters-strategic-collaboration-eli-120000433.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MGTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:39:09+00:00",
    "headline": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
    "summary": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
    "url": "https://finance.yahoo.com/news/coinbase-upgraded-six-flags-downgraded-143909983.html",
    "source": "The Fly",
    "provider": "yfinance",
    "raw": {
      "id": "84587a25-bd5d-32b7-b6ca-8e09f1a32a54",
      "content": {
        "id": "84587a25-bd5d-32b7-b6ca-8e09f1a32a54",
        "contentType": "STORY",
        "title": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
        "description": "",
        "summary": "Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls",
        "pubDate": "2025-11-10T14:39:09Z",
        "displayTime": "2025-11-10T14:39:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec",
          "originalWidth": 1200,
          "originalHeight": 628,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YHTvjvqtNAYBPYViMXYCow--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 1200,
              "height": 628,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3gfZRz3Jb2im4_aLYVn4g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Fly",
          "url": "https://thefly.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/coinbase-upgraded-six-flags-downgraded-143909983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/coinbase-upgraded-six-flags-downgraded-143909983.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "COIN"
            },
            {
              "symbol": "KMX"
            },
            {
              "symbol": "PCTY"
            },
            {
              "symbol": "JD"
            },
            {
              "symbol": "JDCMF"
            },
            {
              "symbol": "DOCN"
            },
            {
              "symbol": "HAS"
            },
            {
              "symbol": "MNPR"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "NET"
            },
            {
              "symbol": "CUBE"
            },
            {
              "symbol": "CRCL"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "STRD"
            },
            {
              "symbol": "STRF"
            },
            {
              "symbol": "STRK"
            },
            {
              "symbol": "AAOI"
            },
            {
              "symbol": "FUN"
            },
            {
              "symbol": "DKNG"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:33:00+00:00",
    "headline": "Insilico and Lilly Enter a Research & Licensing Collaboration to Advance AI-Driven Drug Discovery",
    "summary": "Insilico Medicine (\"Insilico\"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (\"Lilly\") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.",
    "url": "https://finance.yahoo.com/news/insilico-lilly-enter-research-licensing-143300424.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "87885caa-f507-3fe4-9888-6776864826fe",
      "content": {
        "id": "87885caa-f507-3fe4-9888-6776864826fe",
        "contentType": "STORY",
        "title": "Insilico and Lilly Enter a Research & Licensing Collaboration to Advance AI-Driven Drug Discovery",
        "description": "",
        "summary": "Insilico Medicine (\"Insilico\"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (\"Lilly\") that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.",
        "pubDate": "2025-11-10T14:33:00Z",
        "displayTime": "2025-11-10T14:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/e97a465f7f4e378e2da80fe2f478bd4c",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jrb5JxoK1CzplNQ2wb8UQQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/e97a465f7f4e378e2da80fe2f478bd4c.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AdZGmz88nWhK6eo_YeQVVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e97a465f7f4e378e2da80fe2f478bd4c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/insilico-lilly-enter-research-licensing-143300424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/insilico-lilly-enter-research-licensing-143300424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:19:03+00:00",
    "headline": "Eli Lilly upgraded at Leerink on ’multiple waves’ of obesity drug adoption",
    "summary": "Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.",
    "url": "https://finance.yahoo.com/news/eli-lilly-upgraded-leerink-multiple-141903800.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "4b82dfdc-8cf7-39e4-b93b-34f9e3976d0d",
      "content": {
        "id": "4b82dfdc-8cf7-39e4-b93b-34f9e3976d0d",
        "contentType": "STORY",
        "title": "Eli Lilly upgraded at Leerink on ’multiple waves’ of obesity drug adoption",
        "description": "",
        "summary": "Investing.com -- Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.",
        "pubDate": "2025-11-10T14:19:03Z",
        "displayTime": "2025-11-10T14:19:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-upgraded-leerink-multiple-141903800.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-upgraded-leerink-multiple-141903800.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:12:00+00:00",
    "headline": "Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'",
    "summary": "For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping people express their individuality through what they wear. But he's also seen first-hand the stigma carried by people living with obesity, amplified by society's misunderstanding of the science behind the chronic disease and the persistent belief that obesity is simply a failure of willpower.",
    "url": "https://finance.yahoo.com/news/queer-eyes-tan-france-helps-141200903.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "158e6488-74d9-3c9e-aa4e-e27db00336aa",
      "content": {
        "id": "158e6488-74d9-3c9e-aa4e-e27db00336aa",
        "contentType": "STORY",
        "title": "Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'",
        "description": "",
        "summary": "For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping people express their individuality through what they wear. But he's also seen first-hand the stigma carried by people living with obesity, amplified by society's misunderstanding of the science behind the chronic disease and the persistent belief that obesity is simply a failure of willpower.",
        "pubDate": "2025-11-10T14:12:00Z",
        "displayTime": "2025-11-10T14:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/7b4ccddc95eee6b91ca4141dba391ce8",
          "originalWidth": 300,
          "originalHeight": 156,
          "caption": "Lilly Logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXXKwopP_7JSnSkuJngQTw--~B/aD0xNTY7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7b4ccddc95eee6b91ca4141dba391ce8.cf.webp",
              "width": 300,
              "height": 156,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R_udbzdlPiSNeHKw4.qxqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7b4ccddc95eee6b91ca4141dba391ce8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/queer-eyes-tan-france-helps-141200903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/queer-eyes-tan-france-helps-141200903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:11:02+00:00",
    "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "url": "https://247wallst.com/investing/2025/11/10/here-are-mondays-top-wall-street-analyst-research-calls-advanced-micro-devices-alphabet-apple-eli-lilly-carmax-hubspot-and-more/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ace44efa-7347-3f6a-83c7-287f1c5763b0",
      "content": {
        "id": "ace44efa-7347-3f6a-83c7-287f1c5763b0",
        "contentType": "STORY",
        "title": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
        "description": "",
        "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
        "pubDate": "2025-11-10T14:11:02Z",
        "displayTime": "2025-11-10T14:11:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/ffa12de664351d2add9abe9bb1d08bbf",
          "originalWidth": 1500,
          "originalHeight": 1004,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I1EwqSI1cnGzFGg5FTnRpw--~B/aD0xMDA0O3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/ffa12de664351d2add9abe9bb1d08bbf.cf.webp",
              "width": 1500,
              "height": 1004,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i_i69s68TERJ5ajC3v63sA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/ffa12de664351d2add9abe9bb1d08bbf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/10/here-are-mondays-top-wall-street-analyst-research-calls-advanced-micro-devices-alphabet-apple-eli-lilly-carmax-hubspot-and-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/monday-top-wall-street-analyst-141102621.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMCX"
            },
            {
              "symbol": "EXPE"
            },
            {
              "symbol": "PCTY"
            },
            {
              "symbol": "HUBS"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "RUN"
            },
            {
              "symbol": "TDC"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "JD"
            },
            {
              "symbol": "JDCMF"
            },
            {
              "symbol": "HAS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "KMX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:47:00+00:00",
    "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
    "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
    "url": "https://finance.yahoo.com/news/does-trumps-mfn-policy-put-124700612.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "dcd3dc33-f4d6-38e2-8bf5-54a8b59c80c9",
      "content": {
        "id": "dcd3dc33-f4d6-38e2-8bf5-54a8b59c80c9",
        "contentType": "STORY",
        "title": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
        "description": "",
        "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
        "pubDate": "2025-11-10T12:47:00Z",
        "displayTime": "2025-11-10T12:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/45ce84955e50e6f6403d57bc7fc0152f",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BeJV9aiRXQ9b7W2pfzjOng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45ce84955e50e6f6403d57bc7fc0152f.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trGbfDPxS46b7DPVw4Xb1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45ce84955e50e6f6403d57bc7fc0152f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-trumps-mfn-policy-put-124700612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-trumps-mfn-policy-put-124700612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "PJP"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T06:51:00+00:00",
    "headline": "Lilly picks up an eye gene therapy in deal with MeiraGTx",
    "summary": "The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.",
    "url": "https://www.biopharmadive.com/news/eli-lilly-meiragtx-gene-therapy-ophthalmology-deal-lca4/805048/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "180e4f97-260f-3f62-a26d-d85d302ee07f",
      "content": {
        "id": "180e4f97-260f-3f62-a26d-d85d302ee07f",
        "contentType": "STORY",
        "title": "Lilly picks up an eye gene therapy in deal with MeiraGTx",
        "description": "",
        "summary": "The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.",
        "pubDate": "2025-11-10T06:51:00Z",
        "displayTime": "2025-11-10T06:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/dabed6584335284bacd0fab77b65c57a",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A light beam shines through the retina and lens on an eye exam.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fM.kfF8M1Zk5PTbNv3QY3w--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/dabed6584335284bacd0fab77b65c57a.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uFrmfskQgbSUMM5SV1w0jA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/dabed6584335284bacd0fab77b65c57a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/eli-lilly-meiragtx-gene-therapy-ophthalmology-deal-lca4/805048/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-picks-eye-gene-therapy-065100393.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]